Dr. Tun-Hsun Kuo of Lumosa Therapeutics presented a novel dual function molecule for the treatment of acute ischemic stroke on February 18, at the International Stroke Conference 2016, Los Angeles, USA. The therapeutic potential of DC009 was investigated by using a focal cerebral ischemia induced by arterial thrombosis model in aged mice (12-15 months old). DC009 showed a steady thrombolytic action and superior safety profile compared to vessel recanalization induced by rt-PA. Further, bleeding prolongation of DC009 (up to 30 mg/kg) in studies through tail amputation bleeding assay in mice was not observed; whereas rt-PA (10mg/kg) prolonged the bleeding to >10 folds of normal bleeding time. According to the MTD determined in preliminary toxicity dose range finding studies, safety margin greater than 50 folds was identified in both mouse and rat.

Abstract